Junjie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junjie Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Yeqian Feng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
5 shared publications - Gouping Ding
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
4 shared publications - Xiaodong Wang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
3 shared publications - Qianqian Wang
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University
2 shared publications - Qianqian Wang
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
2 shared publications - Yiping Huang
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Artificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Open AccessArtificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- Open Access
- 20 September 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi
- 20 September 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Open AccessImmune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi
- Open Access
- 26 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Molecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract
- 26 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessMolecular and AI enabled prognostication in endometrial cancer a 2015 to 2024 bibliometric Atlas and critical review
Background Endometrial cancer (EC) is a leading gynecologic malignancy with increasing incidence and mortality, particularly in high-income countries. Traditional prognostic models based on clinicopathological features often fail to accurately stratify risk, especially in early-stage and low-risk cases. Methods A bibliometric analysis was performed on research articles published between 2015 and 2024, sourced from the Web of Science and Scopus databases. The analysis included publications on prognostic or risk models in EC and assessed key trends and themes within the field. Results The study reveals a significant shift toward molecular-based stratification, particularly with the Cancer Genome Atlas (TCGA) subtypes, and the incorporation of AI-driven models. Molecular markers, such as POLE-ultramutated and p53-abnormal tumors, alongside biomarkers like HE4 and L1CAM, offer improved prognostic accuracy. AI models, including radiomics and deep learning approaches, show promise in predicting disease recurrence and patient outcomes. Conclusion Advances in molecular classification and AI have improved EC prognostication. However, challenges remain in prospective validation and broader clinical implementation. Future research should focus on multi-omics integration and international collaboration to improve the accuracy and applicability of EC prognostic models. Graphical Abstract
- Open Access
- 7 February 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis
- 7 February 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessRewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189536
Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade
- 23 January 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189536
Top Cited PapersOpen AccessPrecision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade